Fig. 5: Combination treatment of navitoclax with trametinib reduces tumor growth in zebrafish xenografts. | Cell Death & Disease

Fig. 5: Combination treatment of navitoclax with trametinib reduces tumor growth in zebrafish xenografts.

From: High content-imaging drug synergy screening identifies specific senescence-related vulnerabilities of mesenchymal neuroblastomas

Fig. 5

A Left: Waterfall plot shows the change in tumor volume (24hpi–72hpi) of each individual xenograft, treated with DMSO or trametinib (250 nM) and navitoclax (10 µM). Tumor volume was calculated based on a z-stack of confocal fluorescent images, stained with DiD. Right: Dot plot shows a significant difference in tumor volume between control and treated xenografts of four individual experiments (n = 78 CDX, n = 38 PDX). CDX cell line derived (SH-EP), PDX patient-derived (INF_R_1632_LTC). Statistical analysis was performed with the Mann–Whitney test, ****p ≤ 0.0001. B Representative images of zebrafish embryos xenotransplanted with SH-EP neuroblastoma cells. Brightfield images were merged with the maximum intensity projection of z-stack fluorescent images of tumor cells stained with the fluorescent cell labeling dye DiD. Early larvae were treated with navitoclax 10 µM and trametinib 250 nM for 48 h (24hpi–72hpi). Scale bar = 500 µm. C Immunofluorescence of patient-derived neuroblastoma cells used for zebrafish embryo injections with YAP1 (mesenchymal) and NEF-M (adrenergic) markers. The sample INF_R_1632 was obtained through INFORM. Scale bar = 500 µm.

Back to article page